36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile
Authors:
Open Access
- 2 November 2023
- journal article
- abstracts
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 1905